Dizziness is a common chief complaint with an extensive differential diagnosis that ranges from peripheral, central, to nonvestibular conditions. An understanding of nonvestibular conditions will aid accurate diagnosis and initiation of appropriate management. Thus, the objective of this article is to present an overview of nonvestibular etiologies that may plague a dizzy patient and the recommended treatment options.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.otc.2021.05.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Brigatinib in -Related Schwannomatosis with Progressive Tumors.
N Engl J Med
June 2024
From Massachusetts General Hospital and Harvard Medical School (S.R.P., V.L.M.) and the Dana-Farber Cancer Institute (G.F., L.T.) - all in Boston; the NYU Grossman School of Medicine (K.H.Y.) and the Children's Tumor Foundation (A.B.) - both in New York; the University of California, Los Angeles, Los Angeles (P.L.N.); the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami (C.T.D.); the Mayo Clinic, Rochester, MN (D.B.-V.); and Johns Hopkins University, Baltimore (J.O.B.).
Article Synopsis
- Background: -related schwannomatosis (formerly neurofibromatosis type 2) is a progressive tumor syndrome characterized by various tumors including vestibular and nonvestibular schwannomas, meningiomas, and ependymomas, with no approved treatments available.
- Methods: A phase 2 trial was conducted involving patients aged 12 and older with -SWN, treating them daily with 180 mg of oral brigatinib, and evaluating tumor response and safety through a central review committee.
- Results: Out of 40 patients, radiographic response rates were 10% for target tumors and 23% for all tumors, with improvements notably in meningiomas
Delayed Diagnoses in Patients With Dizziness in the US Commonwealth of Virginia and the Tidewater Region.
Otol Neurotol Open
December 2023
Department of Otolaryngology, Eastern Virginia Medical School, Norfolk, Virginia.
Objective: In a region of approximately 1.7 million people (Tidewater, coastal Virginia), identify secondary diagnoses in persons with dizziness.
Methods: This cross-sectional study utilizing TriNetX included individuals in the region of interest diagnosed with dizziness between 2010 and 2020.
Neurofibromatoses.
Hematol Oncol Clin North Am
February 2022
Pappas Center for Neuro-Oncology and Family Center for Neurofibromatosis, Massachusetts General Hospital, Department of Neurology, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA.
The neurofibromatoses are a group of genetic disorders that cause development of nervous system tumors as well as various other tumor and systemic manifestations. Neurofibromatosis type 1 is the most prevalent of these conditions and has the most variable phenotype and highest risk of malignant tumor formation. Neurofibromatosis type 2 has no associated malignant tumors but does carry significant morbidity, including deafness, facial weakness, and physical disability.
View Article and Find Full Text PDFNonvestibular Dizziness.
Otolaryngol Clin North Am
October 2021
Department of Otolaryngology-Head & Neck Surgery, University of California San Francisco School of Medicine, 2233 Post Street, Room 315, San Francisco, CA 94115, USA. Electronic address:
Dizziness is a common chief complaint with an extensive differential diagnosis that ranges from peripheral, central, to nonvestibular conditions. An understanding of nonvestibular conditions will aid accurate diagnosis and initiation of appropriate management. Thus, the objective of this article is to present an overview of nonvestibular etiologies that may plague a dizzy patient and the recommended treatment options.
View Article and Find Full Text PDFDizziness Handicap Inventory in Clinical Evaluation of Dizzy Patients.
Int J Environ Res Public Health
February 2021
Balance Disorders Unit, Department of Otolaryngology, Medical University of Lodz, 90-237 Lodz, Poland.
(1) Objectives: The evaluation of dizzy patients is difficult due to nonspecific symptoms that require a multi-specialist approach. The Dizziness Handicap Inventory (DHI) is widely used in the assessment of dizziness-related disability, but its clinical efficacy needs further expansion. The aim of this study was to identify the subscales of DHI that may correlate with some vestibular or nonvestibular dysfunctions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!